The recommendation was based on results from two Phase III trials showing that Tevimbra plus chemo improved overall survival over chemo alone.

The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.

Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

Patients with EGFR- and MET-altered NSCLC benefited from treatment with the drug combo after progressing on Tagrisso alone.

The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.

The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.

Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.

The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.